in the absence of a submission from the holder of the marketing authorisation:
bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is not recommended for use within NHSScotland.
Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice243KB (PDF)
Medicine details
- Medicine name:
- bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy)
- SMC ID:
- SMC2760
- Indication:
Treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 January 2025